688293 奥浦迈
已收盘 08-13 15:00:01
资讯
新帖
简况
8月13日奥浦迈涨9.20%,招商医药健康产业股票基金重仓该股
证券之星 · 16:36
8月13日奥浦迈涨9.20%,招商医药健康产业股票基金重仓该股
奥浦迈(688293)披露简式权益变动报告书(上海磐信),8月10日股价上涨5.74%
证券之星 · 08-10 22:08
奥浦迈(688293)披露简式权益变动报告书(上海磐信),8月10日股价上涨5.74%
8月10日奥浦迈发布公告,股东减持123.15万股
证券之星 · 08-10 19:01
8月10日奥浦迈发布公告,股东减持123.15万股
8月7日奥浦迈涨17.60%,招商医药健康产业股票基金重仓该股
证券之星 · 08-07
8月7日奥浦迈涨17.60%,招商医药健康产业股票基金重仓该股
股市必读:奥浦迈新发布《奥浦迈:第二届董事会第二十四次会议决议公告》
证券之星 · 08-06
股市必读:奥浦迈新发布《奥浦迈:第二届董事会第二十四次会议决议公告》
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划首次授予结果,8月5日股价下跌0.42%
证券之星 · 08-05
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划首次授予结果,8月5日股价下跌0.42%
奥浦迈(688293)331.91万股限售股将于8月5日解禁,占总股本2.33%
证券之星 · 08-05
奥浦迈(688293)331.91万股限售股将于8月5日解禁,占总股本2.33%
8月4日奥浦迈现1笔大宗交易 机构净买入1611.9万元
证券之星 · 08-04
8月4日奥浦迈现1笔大宗交易 机构净买入1611.9万元
股市必读:奥浦迈新发布《上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2026年第三次临时股东会的法律意见书》
证券之星 · 08-04
股市必读:奥浦迈新发布《上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2026年第三次临时股东会的法律意见书》
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划获股东大会审议通过,8月3日股价下跌1.23%
证券之星 · 08-03
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划获股东大会审议通过,8月3日股价下跌1.23%
每周股票复盘:奥浦迈(688293)331.9万股限售股8月5日上市
证券之星 · 08-02
每周股票复盘:奥浦迈(688293)331.9万股限售股8月5日上市
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划激励对象名单核查意见及公示情况说明,7月27日股价上涨4.29%
证券之星 · 07-27
奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划激励对象名单核查意见及公示情况说明,7月27日股价上涨4.29%
每周股票复盘:奥浦迈(688293)半年报预喜营收增153%
证券之星 · 07-26
每周股票复盘:奥浦迈(688293)半年报预喜营收增153%
奥浦迈(688293)披露公司及全资子公司完成工商变更登记并换发营业执照的公告,7月24日股价下跌6.46%
证券之星 · 07-24
奥浦迈(688293)披露公司及全资子公司完成工商变更登记并换发营业执照的公告,7月24日股价下跌6.46%
7月24日奥浦迈跌6.46%,招商医药健康产业股票基金重仓该股
证券之星 · 07-24
7月24日奥浦迈跌6.46%,招商医药健康产业股票基金重仓该股
股市必读:奥浦迈(688293)预计2026年1-6月营业收入4.5亿元
证券之星 · 07-23
股市必读:奥浦迈(688293)预计2026年1-6月营业收入4.5亿元
奥浦迈(688293)披露2026年半年度业绩预告,7月22日股价上涨5.73%
证券之星 · 07-22
奥浦迈(688293)披露2026年半年度业绩预告,7月22日股价上涨5.73%
奥浦迈最新公告:预计2026年半年度净利润同比增长229%
证券之星 · 07-22
奥浦迈最新公告:预计2026年半年度净利润同比增长229%
7月22日奥浦迈涨5.73%,招商医药健康产业股票基金重仓该股
证券之星 · 07-22
7月22日奥浦迈涨5.73%,招商医药健康产业股票基金重仓该股
奥浦迈涨5.73%,东吴证券二个月前给出“买入”评级
证券之星 · 07-22
奥浦迈涨5.73%,东吴证券二个月前给出“买入”评级
加载更多
公司概况
公司名称:
上海奥浦迈生物科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-09-02
主营业务:
上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是CHO培养基、293培养基、CDMO服务。公司在2025浦东创新创业大会正式获授“大企业开放创新中心(GOI)”。大企业开放创新中心是浦东推动大企业携手创新企业共同成长的有效举措。本次公司获得授牌,不仅是对其产业龙头地位的认可,更标志着奥浦迈以“资本+平台”双轮驱动,系统化推进产业链开放创新的战略进入新阶段。
发行价格:
80.20
{"stockData":{"symbol":"688293","market":"SH","secType":"STK","nameCN":"奥浦迈","latestPrice":67.53,"timestamp":1786604401000,"preClose":61.84,"halted":0,"volume":8978928,"delay":0,"changeRate":0.092,"floatShares":117000000,"shares":142000000,"eps":0.466,"marketStatus":"已收盘","change":5.69,"latestTime":"08-13 15:00:01","open":61.44,"high":69.94,"low":61.08,"amount":595000000,"amplitude":0.1433,"askPrice":67.54,"askSize":4,"bidPrice":67.53,"bidSize":67,"shortable":0,"etf":0,"ttmEps":0.466,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":5,"adr":0,"adjPreClose":61.84,"symbolType":"stock_kcb","openAndCloseTimeList":[[1786584600000,1786591800000],[1786597200000,1786604400000]],"highLimit":68.02,"lowLimit":55.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":142194199,"isCdr":false,"pbRate":3.62,"roa":"--","peRate":144.914163,"roe":"1.44%","epsLYR":0.37,"committee":-0.241573,"marketValue":9602000000,"turnoverRate":0.0766,"status":0,"afterMarket":{"amount":87789,"volume":1300,"close":67.53,"buyVolume":9966,"sellVolume":0,"time":1786606437746,"indexStatus":"已收盘 08-13 15:30:00","preClose":61.84},"floatMarketCap":7912000000},"requestUrl":"/m/hq/s/688293","defaultTab":"news","newsList":[{"id":"2659755132","title":"8月13日奥浦迈涨9.20%,招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659755132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659755132?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:36","pubTimestamp":1786610190,"startTime":"0","endTime":"0","summary":"证券之星消息,8月13日奥浦迈涨9.20%,收盘报67.53元,换手率7.66%,成交量8.98万手,成交额5.95亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共20家,其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。招商医药健康产业股票的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300026849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658014934","title":"奥浦迈(688293)披露简式权益变动报告书(上海磐信),8月10日股价上涨5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658014934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658014934?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:08","pubTimestamp":1786370921,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘,奥浦迈报收于66.85元,较前一交易日上涨5.74%,最新总市值为95.06亿元。近日,奥浦迈披露《简式权益变动报告书》。公告显示,磐信(上海)投资中心作为信息披露义务人,因集中竞价、大宗交易减持及公司总股本变动,导致其持股比例由10.47611%降至4.99997%。本次权益变动后,持有奥浦迈7,109,664股,占总股本的4.99997%,不再为持股5%以上股东。持股变动原因为减持计划实施及公司回购、股权激励、重大资产重组等导致的总股本变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000033725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938674","title":"8月10日奥浦迈发布公告,股东减持123.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658938674?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:01","pubTimestamp":1786359691,"startTime":"0","endTime":"0","summary":"证券之星消息,8月10日奥浦迈发布公告《奥浦迈:简式权益变动报告书(上海磐信)》,其股东北京磐茂投资管理有限公司-磐信(上海)投资中心(有限合伙)于2026年6月4日至2026年8月7日间合计减持123.15万股,占公司目前总股本的0.8661%,变动期间该股股价上涨57.19%,截止8月7日收盘报63.22元。股东增减持详情见下表:根据奥浦迈2026年一季报公布的十大股东详情如下:本文数据来源于奥浦迈公告,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000026804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657351616","title":"8月7日奥浦迈涨17.60%,招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657351616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657351616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092086,"startTime":"0","endTime":"0","summary":"证券之星消息,8月7日奥浦迈涨17.60%创60日新高,收盘报63.22元,换手率6.65%,成交量7.8万手,成交额4.6亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共20家,其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。招商医药健康产业股票的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657252129","title":"股市必读:奥浦迈新发布《奥浦迈:第二届董事会第二十四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657252129","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657252129?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:47","pubTimestamp":1785952032,"startTime":"0","endTime":"0","summary":"奥浦迈:关于调整2026年限制性股票与股票增值权激励计划首次授予激励对象名单的公告上海奥浦迈生物科技股份有限公司于2026年8月5日召开第二届董事会第二十四次会议,审议通过了关于调整2026年限制性股票与股票增值权激励计划首次授予激励对象名单的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523526","title":"奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划首次授予结果,8月5日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523526?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:26","pubTimestamp":1785939977,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘,奥浦迈报收于54.6元,较前一交易日下跌0.42%,最新总市值为77.64亿元。近日,上海奥浦迈生物科技股份有限公司确定2026年限制性股票与股票增值权激励计划的首次授予日,向85名激励对象授予208.00万股第二类限制性股票,授予价格为27.85元/股;向5名激励对象授予5.00万份股票增值权,行权价格为27.85元/股。本次授予条件已满足,激励对象未发生禁止情形,董事会及薪酬与考核委员会均同意本次授予。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593006","title":"奥浦迈(688293)331.91万股限售股将于8月5日解禁,占总股本2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657593006?lang=zh_cn&edition=full","pubTime":"2026-08-05 08:15","pubTimestamp":1785888954,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,奥浦迈于8月5日将有331.91万股限售股份解禁,为公司定向增发机构配售股份,占公司总股本2.33%。最近一年内,该股累计解禁3613.94万股,占总股本的25.42%。本次解禁后,公司还有2502.85万股限售股份,占总股本17.6%。奥浦迈主营业务:从事细胞培养产品与服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500008987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343435","title":"8月4日奥浦迈现1笔大宗交易 机构净买入1611.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343435?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:58","pubTimestamp":1785837504,"startTime":"0","endTime":"0","summary":"证券之星消息,8月4日奥浦迈发生大宗交易,交易数据如下:大宗交易成交价格53.73元,相对当日收盘价折价2.01%,成交30万股,成交金额1611.9万元,买方营业部为机构专用,卖方营业部为国泰海通证券股份有限公司上海长宁区江苏路证券营业部。近三个月该股共发生10笔大宗交易,合计成交3.14万手,折价成交10笔。截至2026年8月4日收盘,奥浦迈报收于54.83元,上涨12.38%,换手率4.63%,成交量5.28万手,成交额2.8亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656032703","title":"股市必读:奥浦迈新发布《上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2026年第三次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656032703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656032703?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:01","pubTimestamp":1785776476,"startTime":"0","endTime":"0","summary":"公司公告汇总:奥浦迈于2026年8月3日召开第三次临时股东会,审议通过2026年限制性股票与股票增值权激励计划相关三项议案,同意票占比99.6982%。公司公告汇总上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2026年第三次临时股东会的法律意见书上海市方达律师事务所就奥浦迈2026年第三次临时股东会的召集和召开程序、出席会议人员资格、表决程序及表决结果等事项出具法律意见书。关联股东已回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656237761","title":"奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划获股东大会审议通过,8月3日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656237761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656237761?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:21","pubTimestamp":1785766883,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,奥浦迈报收于48.79元,较前一交易日下跌1.23%,最新总市值为69.38亿元。近日,奥浦迈发布《2026年第三次临时股东会决议公告》显示,公司于2026年8月3日召开2026年第三次临时股东会,审议通过《关于<公司2026年限制性股票与股票增值权激励计划(草案)>及其摘要的议案》《关于<公司2026年限制性股票与股票增值权激励计划实施考核管理办法>的议案》及《关于提请股东会授权董事会办理公司股权激励计划相关事宜的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316648","title":"每周股票复盘:奥浦迈(688293)331.9万股限售股8月5日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316648?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:55","pubTimestamp":1785606914,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,奥浦迈报收于49.4元,较上周的52.87元下跌6.56%。本周关注点来自公司公告汇总:奥浦迈3,319,144股限售股将于2026年8月5日上市流通,占总股本2.33%。公司公告汇总奥浦迈本次上市流通的限售股为发行股份及支付现金购买资产并募集配套资金之首期一次性发行股份部分,共计3,319,144股,占公司总股本的2.33%,涉及股东4名,限售期为自2026年2月5日起6个月,上市流通日期为2026年8月5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654046575","title":"奥浦迈(688293)披露2026年限制性股票与股票增值权激励计划激励对象名单核查意见及公示情况说明,7月27日股价上涨4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654046575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654046575?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:29","pubTimestamp":1785162555,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘,奥浦迈报收于55.14元,较前一交易日上涨4.29%,最新总市值为78.41亿元。近日,奥浦迈发布《董事会薪酬与考核委员会关于公司2026年限制性股票与股票增值权激励计划激励对象名单的核查意见及公示情况说明》公告。公告显示,公司于2026年7月16日召开董事会,审议通过2026年限制性股票与股票增值权激励计划(草案)。公司于2026年7月17日至7月27日在内部公示了激励对象名单,未收到异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654524560","title":"每周股票复盘:奥浦迈(688293)半年报预喜营收增153%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654524560","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654524560?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:35","pubTimestamp":1785000912,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,奥浦迈报收于52.87元,较上周的51.82元上涨2.03%。本周,奥浦迈7月23日盘中最高价报61.68元。来自业绩披露要点:奥浦迈预计2026年上半年营收约4.5亿元,同比增长约153%。公司公告汇总上海奥浦迈生物科技股份有限公司预计2026年上半年实现营业收入45,000万元左右,同比增长约153%;归属于母公司所有者的净利润12,400万元左右,同比增长约229%;扣除非经常性损益后的净利润4,900万元左右,同比增长约64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653603851","title":"奥浦迈(688293)披露公司及全资子公司完成工商变更登记并换发营业执照的公告,7月24日股价下跌6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653603851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653603851?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:10","pubTimestamp":1784902224,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,奥浦迈报收于52.87元,较前一交易日下跌6.46%,最新总市值为75.18亿元。近日,奥浦迈发布《关于公司及全资子公司完成工商变更登记并换发营业执照的公告》。公告显示,上海奥浦迈生物科技股份有限公司及全资子公司澎立生物医药技术(上海)股份有限公司已完成工商变更登记并换发营业执照。奥浦迈因实施2023年限制性股票激励计划,新增股份26,400股,总股本增至142,194,199股,注册资本变更为14,219.4199万元,并相应修订公司章程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700331","title":"7月24日奥浦迈跌6.46%,招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700331","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700331?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:41","pubTimestamp":1784882482,"startTime":"0","endTime":"0","summary":"证券之星消息,7月24日奥浦迈跌6.46%,收盘报52.87元,换手率4.73%,成交量5.38万手,成交额2.91亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共20家,其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。招商医药健康产业股票的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653640087","title":"股市必读:奥浦迈(688293)预计2026年1-6月营业收入4.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653640087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653640087?lang=zh_cn&edition=full","pubTime":"2026-07-23 01:10","pubTimestamp":1784740220,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,奥浦迈报收于59.44元,上涨5.73%,换手率6.03%,成交量6.86万手,成交额4.08亿元。业绩披露要点业绩预告奥浦迈预计2026年1–6月归属净利润盈利约1.24亿元;营业收入4.5亿元;扣非后净利润盈利约4900万元。奥浦迈:关于2026年半年度计提资产减值准备的公告上海奥浦迈生物科技股份有限公司预计计提信用减值损失和资产减值损失合计1,160.54万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300001262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653668647","title":"奥浦迈(688293)披露2026年半年度业绩预告,7月22日股价上涨5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653668647","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653668647?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:20","pubTimestamp":1784730026,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,奥浦迈报收于59.44元,较前一交易日上涨5.73%,最新总市值为84.52亿元。该股当日开盘56.08元,最高60.66元,最低55.28元,成交额达4.08亿元,换手率为6.03%。近日,奥浦迈发布《关于2026年半年度业绩预告的自愿性披露公告》。公告显示,公司预计2026年上半年实现营业收入45,000万元左右,同比增长约153%;归属于母公司所有者的净利润12,400万元左右,同比增长约229%;扣除非经常性损益后的净利润4,900万元左右,同比增长约64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653050753","title":"奥浦迈最新公告:预计2026年半年度净利润同比增长229%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653050753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653050753?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:55","pubTimestamp":1784710549,"startTime":"0","endTime":"0","summary":"奥浦迈(688293.SH)公告称,预计2026年半年度归属于母公司所有者的净利润为1.24亿元左右,同比增长229%。业绩变动主要系公司完成对澎立生物的收购,合并报表范围变化,以及相关金融负债公允价值变动收益增加。注:公司Q2净利润预计0.85亿,Q1净利润0.39亿,据此计算,Q2净利润预计环比增长116%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653531697","title":"7月22日奥浦迈涨5.73%,招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653531697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653531697?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:44","pubTimestamp":1784709890,"startTime":"0","endTime":"0","summary":"证券之星消息,7月22日奥浦迈涨5.73%创60日新高,收盘报59.44元,换手率6.03%,成交量6.86万手,成交额4.08亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共20家,其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。招商医药健康产业股票的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753928","title":"奥浦迈涨5.73%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653753928?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:44","pubTimestamp":1784709878,"startTime":"0","endTime":"0","summary":"今日奥浦迈(688293)涨5.73%,收盘报59.44元。2026年5月7日,东吴证券研究员朱国广,刘若彤发布了对奥浦迈的研报《2025年报&2026年一季报点评:培养基业务步入快速放量周期,CRO订单高增速》,该研报对奥浦迈给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为33.38%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为太平洋的李啸岩。奥浦迈(688293)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688293"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786614361089,"stockEarnings":[{"period":"1week","weight":0.1326},{"period":"1month","weight":0.3328},{"period":"3month","weight":0.3386},{"period":"6month","weight":0.1802},{"period":"1year","weight":0.1325},{"period":"ytd","weight":0.2678}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0084},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0332},{"period":"1year","weight":0.0766},{"period":"ytd","weight":-0.0056}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海奥浦迈生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"4880人(较上一季度增加21.57%)","perCapita":"24009股","listingDate":"2022-09-02","address":"上海市浦东新区紫萍路908弄28号","registeredCapital":"14219万元","survey":" 上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是CHO培养基、293培养基、CDMO服务。公司在2025浦东创新创业大会正式获授“大企业开放创新中心(GOI)”。大企业开放创新中心是浦东推动大企业携手创新企业共同成长的有效举措。本次公司获得授牌,不仅是对其产业龙头地位的认可,更标志着奥浦迈以“资本+平台”双轮驱动,系统化推进产业链开放创新的战略进入新阶段。","listedPrice":80.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥浦迈,688293,奥浦迈股票,奥浦迈股票老虎,奥浦迈股票老虎国际,奥浦迈行情,奥浦迈股票行情,奥浦迈股价,奥浦迈股市,奥浦迈股票价格,奥浦迈股票交易,奥浦迈股票购买,奥浦迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}